Source Count: 21 | Weighted Score: 41 | Source Confidence: [4/5] | Primary Tier: 2 | Last Updated: March 13, 2026
Keywords: 5-MeO-DMT, Bufo alvarius, Incilius alvarius, toad venom, Sonoran Desert toad, bufotenine, entheogen, psychedelic, synthetic 5-MeO-DMT, conservation, ego dissolution
Category Tags: altered-states, psychedelic, toad-venom, 5-MeO-DMT, conservation
Cross-References: Y_1_01 — Psychedelics · Y_1_09 — Toxins and Venoms · X_2_11 — Ethnobotanical Pharmacology

QUICK SUMMARY

Toad venom — specifically the venom of the Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) — contains 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), one of the most potent psychoactive tryptamines known, producing experiences that are frequently described as the most intense and transformative of all psychedelic encounters: a rapid (onset within 15–30 seconds when smoked), overwhelming, and often ego-dissolving experience lasting 15–45 minutes. The venom is collected by gently "milking" the toad's parotoid glands — a process that does not harm the animal — and the dried secretion is then smoked or vaporized. 5-MeO-DMT acts primarily as a potent agonist at serotonin 5-HT2A and 5-HT1A receptors and is pharmacologically and experientially distinct from N,N-DMT (the active compound in ayahuasca): while N,N-DMT typically produces vivid, complex visual imagery (geometric patterns, entity encounters, elaborate visionary landscapes), 5-MeO-DMT tends to produce a white-out of consciousness — described as dissolution into infinite light, complete annihilation of the sense of self, feelings of oneness with all existence, and experiences variously characterized as "oceanic boundlessness," "nondual awareness," or "ego death." The practice of smoking toad venom has grown enormously in popularity since ~2010, driven by underground ceremonial use, social media, and endorsements from public figures, raising serious conservation concerns for wild toad populations in the Sonoran Desert (Arizona, northwestern Mexico). This has intensified controversy over whether users should shift to synthetic 5-MeO-DMT (which is pharmacologically identical and avoids animal exploitation) versus proponents of "natural" toad medicine who argue the venom contains a complex mixture of compounds with synergistic effects.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Chemistry and Pharmacology

• 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine): a tryptamine alkaloid; naturally occurring in the venom of Incilius alvarius, in several plant species (e.g., Anadenanthera peregrina seeds — yopo, Virola bark), and in human brain tissue and CSF (in trace amounts)
• Primary mechanism: potent agonist at 5-HT2A (mediating psychedelic effects) and 5-HT1A serotonin receptors; also interacts with 5-HT2C, sigma-1 receptors, and monoamine oxidase
• 5-MeO-DMT is approximately 4–10× more potent than N,N-DMT by weight; effective vaporized dose: ~5–20 mg; onset when smoked: ~15–30 seconds; peak: 3–10 minutes; total duration: ~20–45 minutes
• The toad venom also contains bufotenine (5-hydroxy-DMT) and other indole alkaloids, cardiac glycosides (bufotoxins — which are toxic but are largely destroyed by heat during smoking), and various other compounds

1.2 The Sonoran Desert Toad

• Incilius alvarius: the largest native toad in the United States; found in the Sonoran Desert region of Arizona, New Mexico, and northwestern Mexico; largely nocturnal; active during the summer monsoon season (July–September)
• Venom collection: the toad's large parotoid glands (behind the eyes) and leg glands are gently squeezed to express the venom, which is dried on a glass or non-porous surface; the process is non-lethal to the toad if done carefully and the animal is released
• Conservation concern: growing demand for toad venom has led to increased collection pressure on wild populations; I. alvarius is classified as "threatened" in New Mexico and is listed under CITES consideration; Arizona law prohibits possession of the toad without a fishing license, and "self-defense" possession of the venom's psychoactive components is illegal (5-MeO-DMT is Schedule I in the US)

1.3 Subjective Effects

• 5-MeO-DMT produces experiences qualitatively distinct from N,N-DMT:
• Ego dissolution: rapid, complete dissolution of the sense of self — described as "merging with the universe," "becoming nothing and everything simultaneously," or "white-out" (a undifferentiated field of light or energy, without visual content)
• Nondual awareness: the subjective boundary between self and environment collapses; many users describe the experience in terms consistent with mystical/nondual states described in Advaita Vedanta, Dzogchen, and mystical Christianity
• Somatic intensity: strong bodily sensations (heat, pressure, vibration, involuntary vocalization — screaming, crying, laughing); physical release is common
• Challenging experiences: the intensity can be overwhelming; some users experience panic, confusion, or psychological distress; integration afterward is important

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Therapeutic Potential

• Davis et al. (2019): retrospective survey of 362 adults who used 5-MeO-DMT (from toad or synthetic) — 80% reported improvements in anxiety and depression; improvements were correlated with the intensity of the mystical experience and ego dissolution
• Uthaug et al. (2019): prospective study — single inhalation of 5-MeO-DMT from toad venom produced significant reductions in depression, anxiety, and stress at 4-week follow-up, correlated with ratings of ego dissolution and oceanic boundlessness
• Research on 5-MeO-DMT-assisted therapy is in earlier stages than psilocybin or MDMA research; the compound's extreme intensity and brief duration present both advantages (rapid, single-session intervention) and challenges (safety monitoring, integration)

2.2 Synthetic vs. Natural Debate

• Conservation scientists and some psychedelic researchers advocate synthetic 5-MeO-DMT as a sustainable and ethically preferable alternative to toad-derived venom — the molecule is identical and can be produced at scale without impacting wild toad populations
• Proponents of natural toad venom argue that the venom's complex mixture (5-MeO-DMT + bufotenine + other compounds) produces a qualitatively different and more "complete" experience — though controlled comparative studies are lacking

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Ancient Use of Toad Venom

• Claims that ancient Mesoamerican cultures (Olmec, Maya) ritually used toad venom for psychoactive purposes — based on the prominence of toad iconography in Mesoamerican art (e.g., the Olmec toad altars); while suggestive, direct archaeological evidence of toad venom consumption is lacking, and the Mesoamerican toad images may represent different species or have non-psychoactive symbolic meaning

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Toad Venom Cures All Trauma

• [REFUTED] Claims that a single toad venom experience permanently cures PTSD, depression, or addiction — while preliminary evidence suggests therapeutic potential, there are no controlled clinical trials establishing efficacy, and the intensity of the experience can itself be traumatizing without proper preparation, setting, and integration

COUNTER-ARGUMENTS AND CRITICAL PERSPECTIVES

Conservation Threat from Harvesting

Incilius alvarius (formerly Bufo alvarius) populations face significant pressure from individuals capturing toads to extract venom. The species has limited range (Sonoran Desert), and anecdotal reports of population declines in heavily harvested areas have raised conservation concerns. Synthetic 5-MeO-DMT is chemically identical and widely available, making toad harvesting ecologically unnecessary.

Safety Risks of Uncontrolled Administration

5-MeO-DMT produces rapid, intense autonomic and psychological effects including apnea, muscle rigidity, loss of consciousness, and cardiovascular stress. Deaths have been reported in uncontrolled settings. The smoked toad venom preparation contains multiple bioactive compounds (bufotenine, cardiotoxic bufadienolides) beyond 5-MeO-DMT, adding toxicological complexity absent from purified synthetic material.

No Controlled Clinical Trials as of 2025

Despite growing interest and observational/survey data suggesting mental health benefits, no randomized controlled clinical trial of 5-MeO-DMT for any psychiatric indication has been completed and published. Observational data suffer from self-selection bias, expectation effects, and absence of placebo controls. The evidence base lags far behind psilocybin and MDMA.

Cultural Appropriation and Indigenous Rights

The popularization of toad venom ceremonies by non-Indigenous practitioners raises concerns about cultural appropriation of Seri and Yaqui traditional knowledge. The rapid commercialization of "toad ceremonies" often lacks the cultural and spiritual framework of traditional use, and commodifies a practice whose origins and custodianship belong to Indigenous communities.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Most, Albert | 1984 | ∅ | Bufo alvarius: The Psychedelic Toad of the Sonoran Desert | ∅ | ∅ | Denton, TX: Venom Press | ∅ | ∅ | ∅ | ∅ | ∅
2. Davis, Alan K., et al | 2019 | "5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Used in a Naturalistic Group Setting Is Associated with Unintended Improvements in Depression and Anxiety" | American Journal of Drug and Alcohol Abuse | ∅ | 45.2::161–169 | ∅ | ∅ | doi:10.1080/00952990.2018.1545024 | ∅ | ∅ | ∅
3. Uthaug, Malin V., et al. "A Single Inhalation of Vapor from Dried Toad Secretion Containing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) in a Naturalistic Setting Is Related to Sustained Enhancement of Satisfaction with Life, Mindfulness-Related Capacities; a Decrement of Psychopathological Symptoms." | 2019 | ∅ | Psychopharmacology | ∅ | 236.9::2653–2666 | ∅ | ∅ | doi:10.1007/s00213-019-05236-w | ∅ | ∅ | ∅
4. Weil, Andrew T.; Wade Davis | 1994 | "Bufo alvarius: A Potent Hallucinogen of Animal Origin" | Journal of Ethnopharmacology | ∅ | 2::1–8 | 41.1- | ∅ | doi:10.1016/0378-8741(94)90051-5 | ∅ | ∅ | ∅
5. Shen, Hong-Wu, et al | 2014 | "Psychedelics and Other Hallucinogens: Pharmacology, Clinical Implications, and Emerging Evidence of Efficacy" | Advances in Pharmacology | ∅ | 69::71–119 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
6. Rätsch, Christian | 2005 | ∅ | The Encyclopedia of Psychoactive Plants: Ethnopharmacology and Its Applications | ∅ | ∅ | Rochester, VT: Park Street Press | ∅ | ∅ | ∅ | ∅ | ∅
7. Lancelotta, Rafael; Alan K | 2020 | "Use of Benefit Enhancement Strategies Among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users" | Journal of Psychoactive Drugs | ∅ | 52.3::243–251 | Davis | ∅ | doi:10.1080/02791072.2020.1737763 | ∅ | ∅ | ∅
8. Sherwood, Alaina M.; Alexander T | 1997 | "5-MeO-DMT" | TiHKAL: The Continuation | ∅ | ∅ | Shulgin | ∅ | doi:10.1023/a:1009922516904 | ∅ | ∅ | In Berkeley: Transform Press
9. Ermakova, Alina O., et al | 2022 | "Retrospective Analysis of Naturalistic 5-MeO-DMT Use" | Psychopharmacology | ∅ | 239.6::1697–1710 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Barsuglia, Joseph P., et al | 2018 | "Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison with a Prior Psilocybin Study" | Frontiers in Psychology | ∅ | 9::2459 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Reckweg, Joost T., et al | 2022 | "A Systematic Review of the Clinical Pharmacology and Toxicology of 5-MeO-DMT" | Journal of Psychopharmacology | ∅ | 36.3::273–294 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
12. Ott, Jonathan | 1997 | "Pharmahuasca, Anahuasca, and Voacanga: Human Pharmacology of Oral DMT Plus Harmine" | Yearbook for Ethnomedicine and the Study of Consciousness | ∅ | 6::241–260 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. Szabo, Attila, et al | 2016 | "Dimethyltryptamine (DMT): A Biochemical Swiss Army Knife in Neuroinflammation and Neuroprotection" | Neural Regeneration Research | ∅ | 11.3::396–397 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Shulgin, Alexander T.; Ann Shulgin | 1997 | ∅ | TiHKAL: The Continuation | ∅ | ∅ | Berkeley: Transform Press | ∅ | isbn:9780963009692 | ∅ | ∅ | ∅
15. Nichols, David E | 2018 | "N,N-Dimethyltryptamine and the Pineal Gland: Separating Fact from Myth" | Journal of Psychopharmacology | ∅ | 32.1::30–36 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
16. Griffiths, Roland R., et al. e0214377 | 2019 | "Survey of Subjective 'God Encounter Experiences': Comparisons among Naturally Occurring Experiences and Those Occasioned by the Classic Psychedelics" | PLOS ONE | ∅ | 14.4:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
17. Halberstadt, Adam L.; Mark A | 2011 | "Multiple Receptors Contribute to the Behavioral Effects of Indoleamine Hallucinogens" | Neuropharmacology | ∅ | 61.3::364–381 | Geyer | ∅ | ∅ | ∅ | ∅ | ∅
18. Winkelman, Michael | 2017 | "The Mechanisms of Psychedelic Visionary Experiences" | Frontiers in Neuroscience | ∅ | 11::539 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
19. Davis, Alan K., et al | 2019 | "5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Used in a Naturalistic Group Setting Is Associated with Unintended Improvements in Depression and Anxiety" | American Journal of Drug and Alcohol Abuse | ∅ | 45.2::161–169 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
20. Morales-García, José A., et al | 2020 | "N,N-Dimethyltryptamine Compound Found in the Hallucinogenic Tea Ayahuasca, Regulates Adult Neurogenesis In Vitro and In Vivo" | Translational Psychiatry | ∅ | 10::331 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
21. Cassels, Bruce K.; Patricio Sáez-Briones | 2018 | "Dark Classics in Chemical Neuroscience: Mescaline" | ACS Chemical Neuroscience | ∅ | 9.10::2448–2458 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/0378-8741(94)90051-5. Corpus hygiene campaign, Phase 4, 2026-07-29.